# Tetra-O-Methyl Nordihydroguaiaretic Acid in Treating Patients With Recurrent High-Grade Glioma

> **NCT00404248** · PHASE1,PHASE2 · COMPLETED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 35 (actual)

## Conditions studied

- Brain and Central Nervous System Tumors

## Interventions

- **DRUG:** terameprocol
- **OTHER:** pharmacological study

## Key facts

- **NCT ID:** NCT00404248
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-01
- **Primary completion:** 2009-06
- **Final completion:** 2012-02
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2019-03-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00404248

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00404248, "Tetra-O-Methyl Nordihydroguaiaretic Acid in Treating Patients With Recurrent High-Grade Glioma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00404248. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*